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Abstract
An easily implementable strategy to reduce treatment failures in severe bacterial infections
is to combine already available antibiotics. However, most in vitro combination assays are
performed by exposing standard bacterial inocula to constant concentrations of antibiotics
over less than 24h, which can be poorly representative of clinical situations. The aim of this
study was to assess the ability of static and dynamic in vitro Time-Kill Studies (TKS) to iden-
tify the potential benefits of an antibiotic combination (here, amikacin and vancomycin) on
two different inoculum sizes of two S. aureus strains. In the static TKS (sTKS), performed by
exposing both strains over 24h to constant antibiotic concentrations, the activity of the two
drugs combined was not significantly different the better drug used alone. However, the
dynamic TKS (dTKS) performed over 5 days by exposing one strain to fluctuating concen-
trations representative of those observed in patients showed that, with the large inoculum,
the activities of the drugs, used alone or in combination, significantly differed over time. Van-
comycin did not kill bacteria, amikacin led to bacterial regrowth whereas the combination
progressively decreased the bacterial load. Thus, dTKS revealed an enhanced effect of the
combination on a large inoculum not observed in sTKS. The discrepancy between the sTKS
and dTKS results highlights that the assessment of the efficacy of a combination for severe
infections associated with a high bacterial load could be demanding. These situations proba-
bly require the implementation of dynamic assays over the entire expected treatment dura-
tion rather than the sole static assays performed with steady drug concentrations over 24h.
Introduction
The recalcitrance of severe, chronic bacterial infections to antibiotic treatments, due to toler-
ance or resistance, is necessitating a search for new antimicrobial strategies. One therapeutic
option to extend the spectrum, minimize the emergence of resistance or enhance the
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bactericidal activity, and which can be easily and rapidly implemented, is to use a combination
of existing antimicrobials [1,2]. However, the potential advantage of the combination for man-
aging an infection has to be assessed in vitro before its implementation in clinical practice.
Currently, one of the most commonly used in vitro assays to evaluate the efficacy of a combina-
tion is the checkerboard assay (CA). This is based on a similar method to the one used for
MIC determination and involves exposure of a standard inoculum of 5.7 log10 CFU/mL [3] to
constant concentrations of one or two drugs followed by assessment of the turbidity after incu-
bating the mixture for 16–20 hours. These CA results are used to classify the combination in
one of three categories: synergy, indifference or antagonism [4]. Another more time-consum-
ing method is to carry out static time-kill studies (sTKS) in which constant concentrations of
drugs are used to monitor the kinetics of bacterial killing over time [5–8]. sTKS is a more
quantitative approach than CA as the bacterial counts during exposure to the drugs alone or in
combination are compared over 24 h. However, although both CA and sTKS assays are inex-
pensive and quite easy to perform, their limitations include short duration of the assay and the
exposure to constant concentrations of drugs. Indeed, due to the absence of broth renewal,
both assays take less than 24 hours, which can prevent the detection of potential bacterial
regrowth, predictive of a relapse in the patient [9], or of progressive activity leading to bacterial
eradication after several days of treatment. Thus, an exposure to constant concentrations does
not reflect the behaviour of drugs in patients since the phenomena of drug absorption, metab-
olism and elimination lead to fluctuating concentrations over time and to a potential exposure
of bacteria to sub-inhibitory concentrations which can promote the development of resistance
[10]. A Hollow-Fiber (HF) infection model has been proposed to overcome these limitations
[11]. This model is used in dynamic time-kill studies (dTKS) to follow the evolution of a bacte-
rial population exposed to antibiotic concentrations that are similar to those observed in
patients treated over several days.
Although many studies of antibiotic combinations have focused on standard inoculum
sizes, infections that are refractory to treatments and require an improved antibiotic strategy
are mainly associated with biofilms and a large bacterial load. Moreover, an inoculum effect
that reduces antibacterial activity on large bacterial population has been described for many
drugs including vancomycin against inoculum sizes of Staphylococcus (S.) aureus strains rang-
ing from 8 to 9.5 log10 CFU/mL [12,13]. We can therefore conclude that in vitro assessments
of antibiotic combinations need to be performed in conditions that could more accurately pre-
dict their efficacy against severe refractory infections associated with large inocula. Besides, the
use of Mueller-Hinton Broth (MHB) was shown to be poorly predictive of in vivo outcomes
for some specific cases [14].
The aim of this study was not to promote the use of one specific combination but rather to
detect discrepancies in the assessments of the efficacy of the same antibiotic combination by
using different methods, culture media or inoculum sizes. Thus, we conducted the experi-
ments with one selected combination to test our hypothesis which was the combination of
vancomycin and an aminoglycoside recommended as the empirical treatment of some natural
and prosthetic cardiac endocarditis [15]. The combination of vancomycin and amikacin was
also previously investigated on S. aureus under static conditions [16].
We compared the efficacy of this combination on standard (around 5 log10 CFU/mL) and
large (around 9 log10 CFU/mL) inocula of two S. aureus strains by performing CA, sTKS and
dTKS in different media. For sTKS, the inocula were exposed for 24 hours to the maximum free
plasma concentrations obtained in patients at the current dosing regimen, i.e. after one adminis-
tration of 15mg/kg amikacin [17] and/or 1 g of vancomycin by IV route [18]. For dTKS in a HF
model, the inocula were exposed for 5 days to fluctuating concentrations, as could be observed
in patients treated once a day with amikacin and/or every 12h with vancomycin [19,20].
Static and dynamic assays to evaluate antimicrobials drugs combinations
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Material and methods
Bacterial strains
A Methicillin Resistant S. aureus (MRSA) ATCC 33591 and a Methicillin Susceptible S. aureus
MSSA (MSSA) HG001, derived from NCTC 8325, were used for the CA and for sTKS with
constant antibiotic concentrations. The MSSA strain HG001 was used for the dTKS with fluc-
tuating antibiotic concentrations in the HF model. Stock cultures of the bacteria were pre-
served at -80˚C in MHB (Sigma-Aldrich, Saint Quentin-Fallavier, France) supplemented with
15% glycerol. Before each assay, 10μL of the bacterial suspension was incubated overnight at
37˚C on a Mueller-Hinton agar plate.
Antimicrobial agents
Amikacin sulfate powder (Amikacine Mylan) and vancomycin chlorhydrate powder (Vanco-
mycin Sandoz) for intravenous administration were used to prepare antibiotic stock solutions
in water at desired concentrations and stored at -20˚C for less than 1 month.
Antibiotic solutions were thawed and diluted to desired concentrations just before use.
Minimal inhibitory concentration (MIC) determination
The MICs of vancomycin and amikacin for the MRSA and MSSA strains were performed in
three independent experiments by broth microdilution with cation adjusted-MHB (Mueller-
Hinton II, Sigma Aldrich, Saint-Quentin-Fallavier, France) according to the CLSI reference
methods [3] and also in Roswell Park Medium Institute 1640 medium (RPMI) (Gibco, Ther-
mofischer Scientific, MA, USA). Briefly, a bacterial suspension diluted in MHB or RPMI to
give a final organism density of 5.7 log10 CFU/mL was added to wells of a microtiter plate con-
taining serial 2-fold dilutions of vancomycin or amikacin. Bacterial growth was recorded after
incubation for 18 hours at 35˚C.
Checkerboard assays (CA)
The combined effect of vancomycin and amikacin on the tested S. aureus strains was first eval-
uated by CA in MHB and RPMI [4]. Briefly, a bacterial suspension diluted in MHB or RPMI
to give a final organism density of 5.7 log10 CFU/mL was added to wells of a microtiter plate
containing serial 2-fold dilutions of amikacin along the ordinate and serial 2-fold dilutions of
vancomycin along the abscissa. After incubation at 35˚C for 18 hours, the MIC of both drugs
were determined in wells containing one drug and in wells containing the combination of
both drugs. The Fractional Inhibitory Concentration (FIC) index was then calculated accord-
ing to Eq 1.
FIC index ¼
MIC of amikacin in combination
MIC of amikacin alone
þ
MIC of vancomycin in combination
MIC of vancomycin alone
ð1Þ
According to Odds [4], synergism is defined as an FIC index< 0.5, the absence of interac-
tion as an FIC index between 0.5 and 4 and antagonism as an FIC index> 4. These assays
were performed in triplicate.
sTKS (constant antibiotic concentrations)
A few colonies from an overnight culture of S. aureus were grown at 37˚C for 18 h in MHB or
RPMI. The bacterial suspension was then centrifuged for 10 min at 3000g and the bacteria
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were resuspended in fresh pre-warmed MHB or RPMI and diluted to obtain standard (5.0
log10 CFU/mL) or large (9.0 log10 CFU/mL) bacterial inocula in MHB or RPMI.
Each inoculum size was exposed to no drug (control), 18 μg/mL of vancomycin, 70 μg/mL
of amikacin or both for 24 hours corresponding to the maximum free plasma concentrations
of the antibiotics when administered at their current dosing regimen. The intravenous admin-
istration of 1g of vancomycin is described to lead to a total peak concentration of 32μg/mL
[21]. However, since vancomycin binding to plasma proteins is of 45% [22] and since bound
vancomycin is not active on bacteria [23], the vancomycin tested concentration in this in vitro
sTKS experiment was equal to the free maximal plasmatic concentration of 18μg/mL [18]. The
administration of 15mg/kg of amikacin is described to achieve a free peak plasma concentra-
tion between 60 and 80μg/mL with a negligible binding and we decided to reproduce a peak
mean concentration of 70μg/mL [24]. So, in these sTKS experiments, that the highest free drug
concentrations achievable in patients were maintained over 24 h in tubes whereas in patients,
the concentrations would decrease due to elimination process. The activity of the antibiotics
was considered as bactericidal when we observed a reduction of the bacterial burden of more
than 3 log10 CFU/mL. Samples were collected from each suspension at 0, 2, 4, 8 and 24h to
count the viable bacteria. All experiments were performed in duplicate.
dTKS (fluctuating antibiotic concentrations)
A Hollow-Fiber model was used to assess the antibacterial activity of the combination of ami-
kacin and vancomycin on S. aureus during exposure to fluctuating clinically-relevant antibi-
otic concentrations. Basically, the HF model includes a cartridge with capillaries composed of
a semipermeable polysulfone membrane. The pore size of the capillaries (42kDa) allows equili-
bration of the concentrations of chemicals which circulate through the central and peripheral
compartments by means of a peristaltic pump (Duet pump, FiberCell Systems, Inc., Frederick,
MD, USA) while the bacteria stay confined to the extracapillary space in the peripheral
compartment.
Twenty milliliters of a suspension containing 5.0 log10 CFU/mL of MSSA were inoculated
into the extracapillary space of a hollow-fiber cartridge (C2011 polysulfone cartridge, FiberCell
Systems, Inc., Frederick, MD, USA) and incubated at 37˚C. The antibiotics were added either
30 min later (standard inoculum assays) or 3 days later (large inoculum assays). For each
experiment, the exposure to amikacin and/or vancomycin lasted 5 days to simulate the phar-
macokinetic profiles of patients receiving the antibiotics at current dosing regimens i.e. 15mg/
kg amikacin once a day [24] and/or 1 g vancomycin twice a day [25] corresponding to maxi-
mum free concentrations (Cmax) in the central compartment of 70μg/mL for amikacin and
18μg/mL for vancomycin by considering a plasma protein binding negligible for amikacin and
equal to 45% for vancomycin. Previous studies showed that there were no issue with the drug
binding to the polysulfone fibers [18,26,27]. The drugs were continuously diluted by means of
a second peristaltic pump (MiniRythmic PN+, SMD, Fleury sur Orne, France) to simulate a
mean elimination half-life of 4 hours, that could be observed for amikacin and vancomycin in
patients [19,20].
One milliliter samples were collected aseptically from the extracapillary space in the HF car-
tridge to count bacteria 0, 2, 4, 6, 8, 10, 24, 34, 48, 58, 72, 80, 96 and 104h after the first antibi-
otic administration. The experiments, including controls and exposure to amikacin and
vancomycin in monotherapy or in combination, were performed in duplicate for the high
inoculum and in one experiment for the standard inoculum. Due to the small number of
assays and the small number of bacterial strains used in this study, we could not perform statis-
tical analysis.
Static and dynamic assays to evaluate antimicrobials drugs combinations
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The general design of the study is indicated in Table 1.
Bacterial counts in TKS
The sampled bacterial suspensions were centrifuged at 3000g for 5 min, the supernatant was
discarded, and the pellet was resuspended in NaCl 0.9%. The suspension was then serially
diluted and plated in triplicate on tryptic soy agar supplemented with magnesium sulfate and
activated charcoal to prevent antibiotic carry-over effects. The colonies were counted after
overnight incubation at 37˚C. The limit of detection (LOD) was 2.5 log10 CFU/mL.
Statistical analysis
The bacterial counts obtained from 0 to 24 h (sTKS and in dTKS) and from 0 to 104h (dTKS)
with the same strain, inoculum size and broth were analyzed with a two-way ANOVA to test
the effect of the sampling time and of the treatment (amikacin and vancomycin alone or in
combination) with repeated measures (Systat 12 software). When the two-way ANOVA gave a
p-value < 0.05 for interaction between the time and treatment factors or for the treatment fac-
tor, a pairwise comparison of the different treatments was performed with a Tukey test with a
correction for multiplicity.
Results
MIC
The MICs of vancomycin and amikacin for the MRSA and the MSSA strains in MHB and in
RPMI are given in Table 2. The susceptible or intermediate status of both strains to both
drugs, independently to the resistance to methicillin, was targeted to allow the detection of an
advantage of the combination.
Based on the EUCAST breakpoints (standard determination with MHB) [28], both strains
were considered as susceptible to vancomycin. The MSSA strain was considered as susceptible
to amikacin and the MRSA strain showed an intermediate susceptibility to amikacin.
Checkerboard assays
To assess the bactericidal activity of a combination of amikacin and vancomycin on S. aureus,
CA were performed in duplicate for the two strains in MHB and RPMI.
The FIC index of amikacin and vancomycin for each of the 2 tested strains, ranged between
1 and 1.5 in both MHB and RPMI, meaning that under the classical conditions of this CA, no
interaction (no synergy or antagonism) was demonstrated between these two antibiotics [4].
sTKS
We then assessed the activity of constant concentrations of vancomycin at 18μg/mL and of
amikacin at 70μg/mL, used alone or in combination, for 24hours in MHB and RPMI on a
large initial S. aureus bacterial burden of 8.7 ± 0.4 log10 CFU/mL and on a standard inoculum
of 4.6 ± 0.4 log10 CFU/mL. The stability of both antibiotics in MHB and RPMI over 24h was
assessed and no significant degradation of the antibiotics was observed after 24h at 37˚C.
The time-kill curves obtained by exposing the different inoculum sizes of the two strains to
antibiotics are shown in Fig 1.
In absence of antibiotic, the bacterial counts obtained after incubating the initial standard
inocula for 24 hours, ranged between 7.8 ± 0.1 log10 CFU/mL and 8.3 ± 0.1 log10 CFU/mL for
both strains in MHB and RPMI. The size of the initial large inoculum remained stable with bac-
terial counts ranging from 8.6 ± 0.1 log10 CFU/mL to 8.8 ± 0.2 log10 CFU/mL after 24 hours.
Static and dynamic assays to evaluate antimicrobials drugs combinations
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Vancomycin alone was bactericidal on standard inocula of the two strains in MHB and in
RPMI since it reduced the bacterial burden to below the LOD after 8 to 24h of antibiotic expo-
sure. Exposure of a large inoculum to vancomycin for 24 h did not reduce the bacterial popula-
tions except for the MRSA strain in RPMI where the bacterial population was reduced by 1.4
log10 CFU/mL.
Amikacin alone was bactericidal on the standard inoculum of the MSSA strain and reduced
the bacterial counts to below the LOD within less than 8h in both media. The reduction of the
standard inoculum was smaller for the MRSA strain for which the bacterial counts were
4.8 ± 0.1 and 5.4 ± 0.5 log10 CFU/mL in MHB and in RPMI respectively after 24h of exposure.
These counts were 3 log10 CFU/mL less than the counts in control experiments but close to the
initial bacterial counts, thereby demonstrating a bacteriostatic effect. The bacterial populations
in large inocula were not reduced by exposure for 24 h to amikacin alone except for the MSSA
strain in RPMI where the population was reduced by 3.6 log10 CFU/mL.
The combination of amikacin and vancomycin at constant concentrations over 24 hours
never showed any significant difference from the better of the two drugs used alone. For the
MSSA strain, the combination gave similar results to those obtained with amikacin alone. The
bacterial loads after exposure of the standard inocula to the combination for 24 hours were
below the LOD. For the large inocula, the bacterial counts were 8.0 ± 0.4 log10 CFU/mL and
5.1 ± 0.6 log10 CFU/mL after 24h in MHB and RPMI respectively. For the MRSA strain, the
combination gave similar results to vancomycin used alone. The bacterial counts after exposure
of the standard inocula to the combination for 24 hours were 3.2 ± 0.3 log10 CFU/mL in MHB
and below the LOD in RPMI. For the large initial inocula, the bacterial counts were 8.8 ± 0.5
log10 CFU/mL and 7.1 ± 0.1 log10 CFU/mL after 24 hours in MHB and RPMI respectively.
dTKS
The HF model was applied to assess the efficacy of vancomycin and amikacin used alone or in
combination under dynamic conditions over 5 days in RPMI on a standard inoculum of
5.4 ± 0.3 log10 CFU/mL and on a large inoculum of 9.4 ± 0.3 log10 CFU/mL.
Table 1. General design of the study with all the assays performed on each bacterial strain.
MSSA MRSA
MHB RPMI MHB RPMI
MIC SI SI SI SI
Checkerboard assay SI SI SI SI
sTKS SI and HI SI and HI SI and HI SI and HI
dTKS NA SI and HI NA NA
SI: Standard Inoculum, HI: High (Large) Inoculum, NA: Not Assessed
https://doi.org/10.1371/journal.pone.0211214.t001
Table 2. MICs (μg/mL) of vancomycin and amikacin for the MRSA and the MSSA strains in MHB and in RPMI.
MIC of Vancomycin (μg/mL) MIC of Amikacin (μg/mL)
MHB RPMI MHB RPMI
MRSA ATCC 33591 1 (S) 1 16 (I) 8
MSSA HG001 1 (S) 1 1 (S) 0.5
(S) classified as susceptible according to EUCAST breakpoints
(I) classified as intermediate according to EUCAST breakpoints
https://doi.org/10.1371/journal.pone.0211214.t002
Static and dynamic assays to evaluate antimicrobials drugs combinations
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In dTKS, the antibiotic concentrations fluctuated over time so as to resemble the concentra-
tion profiles observed in patients receiving repeated recommended doses of amikacin and van-
comycin over 5 days. Vancomycin was administered twice a day at a Cmax of 18μg/mL and
amikacin was administered once a day at a Cmax of 70μg/mL. Both antibiotics were continu-
ously diluted to simulate an elimination half-life of 4 hours.
In the absence of antibiotic (control experiments), the standard inocula increased to
9.5 ± 0.4 log10 CFU/mL in 24h. Thereafter, all the inocula (standard and large) increased
slightly over the next 4 days to reach a final bacterial count of 10.8 ± 0.2 log10 CFU/mL at the
end of 5 days.
The time-kill curves for bacteria exposed in the HF model to amikacin and vancomycin
alone or in combination are shown in Fig 2.
On standard inocula, both antibiotics, alone or in combination, decreased the bacterial bur-
den to below the LOD within less than 8h, as had been obtained with a constant antibiotic con-
centration in sTKS. When exposed to amikacin alone or in combination, the bacterial
Fig 1. Time-kill curves of the 2 strains subjected to constant concentrations of antibiotic. Evolution of the bacterial
population (log10 CFU/mL) for the MSSA (A and B) and MRSA (C and D) strains after exposure to 70μg/mL amikacin
(blue) or 18μg/mL vancomycin (green) or the combination of both (red) over 24hours in MHB (A and C) and in
RPMI (B and D). The marks represent the mean ±SD of the bacterial counts for the different tested treatments (n = 2
for each treatment). Curves with open squares represent the bacterial counts on a large initial inoculum and curves
with crosses represent the bacterial counts on a standard initial inoculum. (LOD = 2.5 log10 CFU/mL). For the low
inoculum of MSSA in MHB and RPMI (A and B), there was no difference between drugs alone or in combination. For
the high inoculum of MSSA, there was no difference between drugs in MHB (A) but vancomycin led to significantly
higher bacterial counts than amikacin and the combination in RPMI (B). For the low inoculum of MRSA, there was no
difference between drugs alone or in combination in MHB (C) but amikacin led to significantly higher bacterial counts
than vancomycin and combination in RPMI (D). For the high inoculum of MRSA, there was no difference between
drugs in MHB (C) but amikacin led to significantly higher bacterial counts than the combination in RPMI (D).
https://doi.org/10.1371/journal.pone.0211214.g001
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population remained below the LOD until the end of the experiment whereas the bacterial
population increased from 34h onwards until it was 6.4 log10 CFU/mL at the end of the experi-
ment with vancomycin alone.
Large inocula of bacteria exposed to fluctuating concentrations of vancomycin alone were
never reduced, as in sTKS. After exposure for 5 days, the population size in the HF model was
comparable to that of control experiments, the final bacterial count being 10.0 ± 0.1 log10
CFU/mL. Exposure to fluctuating concentrations of amikacin alone led to a slight reduction of
the bacterial population over the first 24 hours, as had been observed with constant amikacin
concentrations in sTKS. However, the reduction of 0.9 log10 CFU/mL observed on the first
day in the HF model was quite slight and, after 5 days of treatment, the final bacterial count of
9.2 ± 0.7 log10 CFU/mL was very similar to that of the initial population and not much lower
than in control experiments.
When amikacin and vancomycin were used in combination in the HF model, a decrease of
the bacterial population was observed over the first 24 hours, similar to the treatment with
amikacin alone, with bacterial counts of around 8 log10 CFU/mL. However, significant differ-
ent results (from amikacin alone) were obtained after exposure to the combination for 5 days,
Fig 2. Time-kill curves of the MSSA strain subjected to dynamic concentrations of antibiotic. Evolution of the
bacterial population (log10 CFU/mL) after exposure to amikacin or vancomycin alone or the combination of both over
5 days in RPMI. The marks represent the mean ±SD of the bacterial counts for the different tested treatments (black:
control without antibiotic, green: vancomycin twice a day, blue: amikacin once a day, red: amikacin once a day and
vancomycin twice a day. Curves with open squares represent the bacterial counts on a large initial inoculum and
curves with crosses represent the bacterial counts on a standard initial inoculum. (n = 2 for each treatment on the large
inocula and n = 1 for each treatment on the standard inocula) and LOD = 2.5 log10 CFU/mL). The bacterial counts
from 0 to 24 h after exposure to vancomycin were significantly higher (p<0.01) than those obtained with amikacin or
the combination. The bacterial counts from 0 to 104 h were significantly different for each treatment (p<0.01).
https://doi.org/10.1371/journal.pone.0211214.g002
Static and dynamic assays to evaluate antimicrobials drugs combinations
PLOS ONE | https://doi.org/10.1371/journal.pone.0211214 January 23, 2019 8 / 13
the mean final bacterial count of 4.3 ± 1.6 log10 CFU/mL corresponding to an overall reduction
of more than 5 log10 CFU/mL.
This observation of bactericidal activity with the combination after 5 days and no or only
slight activity with both drugs used alone demonstrated a synergy between amikacin and van-
comycin for S. aureus in the HF model.
Discussion
In this study, our objective was to compare the results of antibacterial efficacy of drug combi-
nation obtained by performing checkerboard assays (CA), static Time-Kill studies (sTKS) or
dynamic Time-Kill Studies (dTKS). For this comparison, we selected two antibiotics used for
the management of S. aureus infection, namely amikacin and vancomycin. The activities of the
two drugs, alone or in combination, were investigated on two different inoculum sizes of two
S. aureus strains susceptible to vancomycin and susceptible or intermediate to amikacin. The
efficacy of the antibiotic combination on the tested S. aureus strains was found to differ
depending on the inoculum size and the methods used.
The susceptibility of both strains to vancomycin was confirmed in sTKS by the systematic
eradication of a standard inocula exposed to the concentrations of vancomycin achievable in
patients, and in dTKS by a decrease of bacterial counts of the standard inocula below the LOD
after 8 to 34 hours. In these dynamic experiments, slight bacterial regrowth was observed
which attained 7 log10 CFU/mL after 5 days, despite repeated administrations of vancomycin
twice a day. However, because no bacteria could be detected during 24 hours, we hypothesized
that, in vivo, the immune system in immunocompetent patients could take over from antibi-
otic action to eradicate the bacteria, prevent regrowth and lead to a bacterial cure. Testing two
inoculum sizes revealed an important effect of inoculum size for vancomycin, since no bacteri-
cidal activity (i.e. a reduction of more than 3 log10) was demonstrated on large bacterial inocula
of the two susceptible strains in either culture medium. One hypothesis for this effect is that
bacteria are able to trap and rapidly decrease free vancomycin concentrations in the medium.
Cui et al. [29] described this phenomenon on MRSA and suggested that the thickened peptido-
glycan layers of MRSA could trap free vancomycin. Yanagisawa et al. [30] also demonstrated
that when 4 μg/mL of vancomycin was added to a 7 log10 CFU/mL culture of a MRSA strain,
the concentration of free vancomycin immediately fell from 4 to 3.5 μg/mL suggesting that the
initial trapping by bacteria occurred very rapidly. Other in vitro studies also confirmed this
inoculum effect on vancomycin susceptible MSSA [31] and on vancomycin highly resistant
MRSA strains [32].
For amikacin, the MSSA strain was classified as susceptible whereas the MRSA strain
showed an intermediate susceptibility according to the EUCAST MIC breakpoint [28]. For
aminoglycosides, the fCmax/MIC ratio (peak free plasma concentration divided by the MIC) is
considered as the best index to predict the efficacy of a treatment [33] and targeting a break-
point value of more than 8 to 10 for this ratio is usually recommended to ensure clinical effi-
cacy against the pathogen [34]. When the amikacin concentration tested in sTKS was 70 μg/
mL, the ratios of the tested concentration over the MIC were 70 and 140 in MHB and RPMI
respectively for the MSSA strain, i.e. far higher than the breakpoint value for clinical efficacy.
Indeed, the standard bacterial inoculum was rapidly eradicated after exposure to amikacin in
both sTKS and dTKS. For the MRSA strain, the fCmax/MIC ratios were 4.4 and 8.8 over the
24h of exposure in MHB and RPMI respectively and were lower than or very close to the
breakpoint value, suggesting that antibacterial activity would be uncertain. Our results con-
firmed that amikacin exhibited bacteriostatic but not bactericidal activity on a standard inocu-
lum of the MRSA strain in the two media.
Static and dynamic assays to evaluate antimicrobials drugs combinations
PLOS ONE | https://doi.org/10.1371/journal.pone.0211214 January 23, 2019 9 / 13
Large inocula of MSSA and MRSA bacteria were not eradicated by amikacin in the sTKS.
Thus, the classification of these bacteria as susceptible or intermediate to amikacin, based on
the sole MIC determination, could not be predictive of an antibacterial effect on a large inocu-
lum in sTKS. Similar results had been obtained in previous studies when a large inoculum of
susceptible S. aureus was challenged by another aminoglycoside [35,36].
Our results confirmed that no eradication of the bacterial burden was attained with mono-
therapy in either medium when the inoculum was large.
To assess the potential interest of combining drugs, we first performed a CA which is a
derivative of the MIC determination for drug combinations. This assay, classically carried out
with a standard inoculum, indicated here indifference between amikacin and vancomycin.
This corroborated the sTKS and dTKS results, indicating that the combination did not exhibit
better antibacterial activity against standard inocula than the better drug used alone. For large
inocula, the assessment of combination efficacy cannot be performed by a standardized CA
since this method, like the MIC determination, relies on an assessment of turbidity after incu-
bation for 16–20 h and the initial inoculum therefore needs to be clear and generally below 7
log10 CFU/mL. This means that the efficacy of a combination or of one drug alone can only be
determined by TKS when the inoculum is large.
With standard inocula, amikacin and vancomycin alone or in combination decreased the
bacterial burden to below the limit of detection in less than 24h in sTKS, except for amikacin
on the MRSA strain. Reductions of large bacterial inocula were only observed after exposure
of the MRSA strain to vancomycin alone or in combination and after exposure of the MSSA
strain to amikacin alone or in combination. Thus, in sTKS, the combination never showed a
significant different activity from the better drug used alone and never improved the efficacy
or rate of bacterial killing over monotherapy, as already shown by the CA results.
Classical sTKS have limitations to mimic in vivo conditions due to the brief period of bacte-
rial exposure to the drugs (usually less than 24 h due to the absence of broth renewal) and the
constant concentrations of antibiotic over time. The use of constant concentrations, especially
of antibiotics with short half-lives, may overestimate drug efficacy since the bacteria are con-
tinuously and artificially exposed to the peak concentration. sTKS could also be performed
with lower antibiotic concentrations encountered in vivo at different times after the peak con-
centration. However, these experiments would probably not be more representative of the in
vivo situation since, in vivo, the bacteria exposed to lower concentrations have already been
confronted to the peak drug concentrations with a possible development of phenotypic or
genotypic adaptations contrarily to the conditions of TKS in which the bacteria would be
naïve (never confronted to drug before). The principal interest of the dynamic model is to
focus on the same initial inoculum over time, with the same bacteria exposed to fluctuations of
concentrations over time, as it occurs in vivo. Another key-point is the length of the experi-
ment which can be a crucial issue if the aim is to reveal a slow bactericidal effect, tolerance or
amplification of resistance. In this study, the dTKS with the HF model were conducted over 5
days, but weeks or months have also been described in other experiments using the same
model [27,37]. With the large inoculum, similar results were obtained for sTKS and dTKS over
the first day i.e. bactericidal activity of amikacin and no significant difference between the
combination and amikacin alone, which also agreed with the results obtained with the CA.
However, some effects on the large inoculum were observed from the second to the fifth day in
dTKS, that were not expected from the observation of the CA or sTKS results. The activity of
amikacin alone decreased over the days and the final bacterial load was the same as in the ini-
tial inoculum. Reduced amikacin activity can be due to tolerance, also known as adaptive resis-
tance [38,39], or to the selection of resistance by repeated exposure to fluctuating
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concentrations over 5 days [26] but we did not explore further these hypotheses and were
unable to discriminate between them.
In contrast, from the second to the fifth day, the vancomycin and amikacin combination
produced a progressive decline of the bacterial population and a final reduction of 5.1 log10
CFU/mL, compared to the initial bacterial load. This late enhancement of the bactericidal
activity might result from a sequential activity of amikacin and vancomycin, the activity of
amikacin on the first day reducing the bacterial population and thereby improving the subse-
quent efficacy of vancomycin. So, performing dTKS with fluctuations of antibiotic concentra-
tions over several days might be helpful to understand therapeutic failures even though a
limitation of dynamic in vitro models is the absence of consideration of the immune system.
However, by using a eukaryotic cell culture medium in sTKS experiments it should be possible
to add components of the immune system in further studies.
Conclusion
The use of HFIM to assess the efficacy of antibiotic combinations is quite poorly represented
in the literature and to our knowledge, this study is one the first comparing sTKS and dTKS
with two inoculum sizes in different culture media. By exploring the combination of amikacin
and vancomycin on two S. aureus strains, we showed that for low bacterial loads, all the tested
methods including rapid methods such as MIC determination and CA led to similar results.
However, for high bacterial loads, longer experiments with fluctuating concentrations of drugs
revealed antibacterial effects varying over days which were not observed with shorter experi-
ments. These results suggested that the efficacy of drug combination on infections associated
with a high bacterial load could be difficult to assess and that the relevance of dynamic models
to predict in vivo efficacy should be investigated to further promote the test of combinations in
such models.
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